Prognosis of pseudophakic retinal detachment

In their retrospective review of 400 patients, Christensen and Villumsen concluded that the surgical outcomes of pseudophakic and phakic retinal detachments are comparable. This finding agrees with that in another retrospective review of 243 consecutive phakic and pseudophakic individuals with primary retinal detachment who had had surgical repairs.

However, if we take a closer look at the data presented by Christensen and Villumsen, a major incongruity with the previous studies is encountered. As pointed out by Halberstadt et al., the size of the retinal detachment significantly influences the surgical outcome in pseudophakic and phakic eyes with retinal detachment. In retinal detachments of more than 3 quadrants, the detachment size substantially affects the postoperative results in pseudophakic eyes more than it does phakic eyes. According to Table 3 in the article by Christensen and Villumsen, large detachment of 3 or more quadrants occurred in 69 (24.6%) phakic and 38 (31.7%) pseudophakic individuals. No significant difference in the overall extent of detachments between groups was reported. Therefore, it may be inferred that the pseudophakic group should have done worse in terms of surgical outcome under the influence of a similar proportion of large retinal detachment compared with the phakic group. Other unmentioned confounding factors may have been operating and offsetting the influence of the large detachment in pseudophakic patients.

The authors’ further enlightenment of this issue would be much appreciated.

REFERENCES


Aberrations after intraocular lens implantation

We read with great interest the report by Pesudovs et al. regarding optical aberrations and intraocular lens (IOL) implantation, particularly the authors’ conclusion that “visual performance did not differ despite differences in wavefront aberration.” The
authors state that they found no significant differences in logMAR visual acuity or sine wave contrast sensitivity despite a significant difference in spherical aberration (difference in C_{12} = 0.18 μm for a 6.0 mm pupil, “PMMA-scleral” versus “AcrySof-corneal” groups). The authors do note, however, that “recent reports suggest the visual impact of spherical aberration differences from IOLs can be detected by contrast sensitivity,” and state that their “results contradict this.” Pesudovs et al. specifically cite our work as contradictory to theirs.2

We would like to point out that our work represents only 1 example of a growing body of published evidence that demonstrates improved functional vision with elimination of spherical aberration by means of a modified prolate IOL designed to correct corneal spherical aberration.3–9 One additional unpublished but significant demonstration of improved functional vision with elimination of spherical aberration is reflected in the U.S. Food and Drug Administration–approved labeling for the Tecnis modified prolate IOL (AMO, Inc.), which states that the “spherical aberration of eyes implanted with the Tecnis IOL is not significantly different from zero” and that “there is a meaningful safety benefit for elderly drivers and those with whom they share the road,” as well as “potential improvement in safety under low visibility for other activities of living” http://www.fda.gov/cdrh/ptma/pnmamor04.html (see also, package insert, Foldable Ultraviolet Light-Absorbing Posterior Chamber IOL, Tecnis, with Z-sharp Optic Technology, model Z9000, AMO, Inc.).

It is possible that the apparent contradiction highlighted by Pesudovs et al. may be resolved by the fact that studies demonstrating a correlation between elimination of spherical aberration and improvement in functional vision compare a modified prolate IOL to a variety of spherical IOLs, whereas those studies finding no difference in functional vision compare only spherical IOLs.

MARK PACKER, MD
I. HOWARD FINE, MD
RICHARD S. HOFFMAN, MD
PATRICIA PIERS, MSc

REFERENCES


Reply: We thank Packer et al. for their interest in our article and for the opportunity to comment further on their work on the Tecnis intraocular lens (IOL). Despite a number of reports on the topic, there is not yet convincing evidence that the Tecnis IOL delivers any benefit to real-world visual performance. The articles cited by Packer et al. use a surrogate measure of real-world visual performance in the form of contrast sensitivity (CS) or low contrast visual acuity (LCVA). These data are at least 1 degree of separation away from what happens in the real world. Connecting the 2 relies on the assumption that a contrast domain measure and real-world visual performance are highly correlated. However, evidence suggests that this is not the case. A number of studies have looked at the relationships between visual performance on a range of clinical tests and compared this to self-reported function or practical tests of real-world performance. Contrast domain tests are usually correlated better with real-world performance than high contrast visual acuity tests (HCVA); however, even highly significant correlations do not explain a high proportion of the variance in real-world performance, and differences between tests are not great. For example, in a study comparing real-world performance on a series of tasks with various tests of visual performance, the proportion of variance in real-world performance explained by visual performance was 74% for near HCVA, 64% for edge CS, 61% for distance HCVA, and 48% for peak CS.1 In probably the most comprehensive article on the topic, Rubin et al.2 found self-reported function was more strongly predicted by HCVA (odds ratio 2.39) than by CS (odds ratio 1.85). So while we encourage the use of contrast domain testing and agree that when added to HCVA it gives a more comprehensive appreciation of real-world visual performance, on its own the incremental gain over HCVA is a lot less than is commonly suggested. This misapprehension probably arises from the clinical experience with symptomatic patients with good HCVA who can be shown to have reduced CS. However, routine testing of CS will show that symptomatic patients can have reduced HCVA and normal peak CS.

So what are we to make of research that shows that CS is affected by aberrations but that HCVA is not? This is indeed possible because the redundant information in a high-contrast target makes it less sensitive to image degradation by aberrations, so LCVA is certainly a more sensitive clinical test than HCVA.3 However, visual acuity testing is a more precise test than sinusoidal CS patch charts.4 Indeed, a CS patch test like the Vistech and FACT charts contain serious design flaws that make their use in cataract or refractive surgery outcomes research inappropriate.4,5 Specifically, the FACT chart has a truncated range of measurement so that people with normal vision can see the lowest contrast patch, producing a ceiling effect. Pseudophakes, especially those with low levels of spherical aberration, should have normal vision so many would see the lowest contrast patch. A study using this chart would be less likely to measure a difference between 2 types of IOLs in the presence of a real difference in visual